PMC:7029759 / 819-1111 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"42","span":{"begin":156,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D009841"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"oping new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate f"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T23","span":{"begin":78,"end":82},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T22","span":{"begin":131,"end":139},"obj":"GO:0042571"},{"id":"T21","span":{"begin":195,"end":200},"obj":"NCBITaxon:10239"},{"id":"T20","span":{"begin":205,"end":211},"obj":"SO:0001026"}],"text":"oping new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate f"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":131,"end":139},"obj":"Body_part"},{"id":"T2","span":{"begin":201,"end":204},"obj":"Body_part"},{"id":"T3","span":{"begin":205,"end":211},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84116"}],"text":"oping new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate f"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":78,"end":82},"obj":"Chemical"},{"id":"T2","span":{"begin":156,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_7754"}],"text":"oping new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate f"}

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":52,"end":270},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"oping new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate f"}